Schedule of Events

2017 ASCP Annual Meeting Schedule

View the schedule in the Itinerary Planner HERE!

View the 2017 Program BookOral Abstract BookPoster Abstract Book, and all presenter disclosures!

*UPDATED Information on CME/CE hours.

Hyperlink on the titles below to see the FDA and Federal Agency Plenary Session slides:

 *of special interest to clinicians

Monday, May 29, 2017  
12:00pm – 4:00pm Latin American Symposium*

Francisco Moreno, M.D., University of Arizona, Chair

Health Disparities in Hispanics in the US (Brief Update on Elder Hispanics and Exercise)*, Danny Jimenez, Ph.D., University of Miami

Identifying Patients with Bipolar Disorders in Emergency Departments in Latin American Countries: Comorbidity and Leading Symptoms*, Ruby Castilla Puentes, M.D., Dr.P.H., Johnson and Johnson

Novel Treatments in Obsessive-Compulsive Disorder (Brief Review of Epidemiological Issues Specific to Latinos)*, Carolyn Rodriquez, M.D., Ph.D., Stanford University

Intersections of General Health and Psychiatric Conditions such as PTSD*, Gerardo Villarreal, M.D., University of New Mexico

PTSD and Gender Violence: Ecuador Experience*, Victoria Valdez, M.D., International Federation of Societies of Biological Psychiatry

Pharmacological Updates in Mood Disorders Pharmacology*, Rodrigo Machado-Vieira, M.D., UTHSC at Houston, School of Medicine

Tuesday, May 30, 2017  
8:30am Conference Opening
9:00am – 10:30am Panel Sessions
Implementing Measurement-based Care in Clinical Practice*

Inflammation and Obesity in Depression: Neurobiological Mechanisms and Therapeutic Implications*

The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses*

Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes*

10:30am – 10:45am Break
10:45am – 12:15pm Panel Sessions

Model-based Approaches to Assist Clinical Development of Psychiatric Products

Development of Antidepressants with Novel Mechanisms of Action*

The Development and Selected Performance of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials – is the Juice worth the Squeeze? a Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials Initiative (ACTIVE) 

Targeting Treatment Needs in Women’s Mental Health*

12:15pm – 1:15pm Early Career Lunch (RSVP Only)

Ross Baker, M.D., Otsuka
Michael Davis, M.D., Ph.D., FDA
Vilma Gabbay, M.D., Icahn School of Medicine at Mount Sinai
Raymond Young-Jin Cho, M.D., University of Texas Health Science Center at Houston

1:15pm – 1:45pm NIH Diversity Supplement Program
2:00pm – 4:00pm Pharmaceutical Pipelines
4:00pm – 4:15pm Break
4:15pm – 5:30pm Individual Research Reports
6:15pm – 7:45pm New Investigator Awards Ceremony
Wednesday, May 31, 2017  
6:30am Annual ASCP Fun Run/Walk – Open to all attendees
8:30am – 10:00am Regulatory Plenary

Tiffany Farchione, FDA

Luca Pani, EMA

10:00 am – 10:15am Break
10:15am – 11:15am ASCP Lifetime Awardee Talk
11:15am – 1:00pm Poster Session I with Lunch
1:00pm – 2:30pm Panel Sessions

Optimizing Neuromodulatory and Pharmacologic Approaches to Treatment Refractory Depression*

Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting

Medication or Psychotherapy as First-line Treatment for Posttraumatic Stress Disorder? an Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD*

Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations*

2:30pm – 3:30pm FDA 101 Session (Slides available)
3:30pm – 3:45pm Break
3:45pm – 5:45pm Workshops

Reducing Health Disparities by Promoting Functional and Life-satisfaction Assessments in Research and Clinical Practice: Consensus Guidelines to Enhance Measurement-based Care of Depression*

Tardive Dyskinesia: The Forgotten Adverse Event*Novel Applications of Ketamine*

Hot Button Topics in Negotiation for Mid-career Professionals in Psychopharmacology and Allied Fields*, Andrea Schneider, Speaker

5:45pm – 6:45pm ASCP Business Meeting and Reception (Members Only)
6:45pm – 7:45pm ASCP Reception
Thursday, June 1, 2017  
8:15am – 9:45am Keynote/Plenary: Serving the Needs of the Diverse Population
Social Determinants of Mental Health*, Michael Compton

Patient Centered Approaches to Care/PPRNs*, Andy Nierenberg

Overcoming Engagement Disparities Among Diverse Populations*, Roberto Lewis-Fernandez

9:45am – 10:00am Break
10:00am – 12:30pm Federal Agency Directors Plenary

Grayson Norquist, PCORI

Joshua Gordon, NIMH

Amir Tamiz, NINDS

Richard Nakamura, CSR

Raye Litten, NIAAA

LTC Dennis McGurk, Department of Defense

Kevin Walton, NIDA

12:30pm – 2:00pm Poster Session II with Lunch
2:00pm – 3:30pm Updates Session*

Schizophrenia: What’s New in 2017?* Nina Schooler, Ph.D., SUNY Downstate Medical Center

Update on Anxiety Disorders*, Mark Pollack, M.D., Rush University Medical Center

Neuromodulation*, Sarah Lisanby, M.D., NIMH

3:30pm – 3:45pm Break
3:45pm – 5:45pm Workshop Sessions

Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches*

Rapid-acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development from the Division of Psychiatry Products (DPP), Food and Drug Administration

How to use the Model Psychopharmacology Curriculum in Various Teachings, Ira Glick, Speaker

Friday, June 2, 2017  
8:30am – 10:00am Panel Sessions

New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials

Suicidal Behavior in the Clinical Setting: Relationship Between ADHD, Depression, and Decision-making Capacity*

Neuromodulation with Transcranial Near-infrared Light: Controlled Evidence*

Validly and Reliably Measuring Functional Performance in Dementia Patients across Countries and Languages in Clinical Trials

10:00am – 10:15am Break
10:15am – 11:45am Regulatory Wrap-Up Plenary
12:00pm Meeting Adjourns

 *of special interest to clinicians